Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Eisen

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
Nature Communications|March 13, 2019
A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinomaSaiful E Syafruddin, Paulo Rodrigues, Erika Vojtasova, et al.
Kidney Cancer (Clifton, Va.)|February 12, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE TrialNicola J Lawrence, Andrew Martin, Ian D Davis, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinomaChooi P Lee, Poulam M Patel, Peter J Selby, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2011
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working groupJudith Manola, Patrick Royston, Paul Elson, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinomaCharles S Harmon, Samuel E DePrimo, Robert A Figlin, et al.
Neoplasia (New York, N.Y.)|December 26, 2024
Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell CarcinomaJeannette C Oosterwijk-Wakka, Liesbeth Houkes, Loes F M van der Zanden, et al.
Genes, Chromosomes & Cancer|October 30, 2013
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinomaLucy Gossage, Muhammed Murtaza, Andrew F Slatter, et al.
The Lancet. Oncology|September 11, 2012
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen, Heikki Joensuu, Paul D Nathan, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
Nature Communications|March 13, 2019
A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinomaSaiful E Syafruddin, Paulo Rodrigues, Erika Vojtasova, et al.
Kidney Cancer (Clifton, Va.)|February 12, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE TrialNicola J Lawrence, Andrew Martin, Ian D Davis, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinomaChooi P Lee, Poulam M Patel, Peter J Selby, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2011
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working groupJudith Manola, Patrick Royston, Paul Elson, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinomaCharles S Harmon, Samuel E DePrimo, Robert A Figlin, et al.
Neoplasia (New York, N.Y.)|December 26, 2024
Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell CarcinomaJeannette C Oosterwijk-Wakka, Liesbeth Houkes, Loes F M van der Zanden, et al.
Genes, Chromosomes & Cancer|October 30, 2013
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinomaLucy Gossage, Muhammed Murtaza, Andrew F Slatter, et al.
The Lancet. Oncology|September 11, 2012
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen, Heikki Joensuu, Paul D Nathan, et al.
Pageof 12